Benign renal masses are noncancerous growths or lesions of the kidney discovered — most often incidentally on imaging performed for another reason — in a significant portion of the population. Simple cysts are found in the majority of adults over 50. The critical clinical task when any kidney mass is identified is distinguishing benign lesions from kidney cancer, because the two groups require completely different management. MRI provides the tissue characterization needed to make this distinction with high accuracy, frequently eliminating the need for biopsy.
The spectrum of renal masses spans from the entirely benign to the life-threatening, and accurate characterization determines management. A simple cyst requires no follow-up. A Bosniak III complex cyst has a 50% malignancy risk and warrants surgical evaluation. A macroscopic fat-containing angiomyolipoma is confidently identified as benign by MRI — but a fat-poor angiomyolipoma can be indistinguishable from clear cell renal cell carcinoma on CT and requires MRI's chemical shift sequences for differentiation. The adrenal gland — which sits atop each kidney — must also be evaluated simultaneously on every renal mass MRI, as adrenal masses are common incidental findings that require their own characterization.
Causes
Varies by mass type.
Simple renal cysts — the most common kidney lesion by a wide margin — form when individual renal tubules become obstructed, dilate, and fill with filtrate, progressively detaching from the parent tubule and enlarging over years. They increase dramatically in prevalence with age: rare before age 30, present in approximately 50% of people over 50, and nearly universal in older adults. They have no malignant potential and represent a normal aging change in most cases. Angiomyolipomas (AMLs) are benign mesenchymal tumors composed of fat, smooth muscle, and abnormal thick-walled blood vessels — the fat content is their defining imaging feature and the basis for confident MRI diagnosis. The abnormal vessels within AMLs lack the normal elastic tissue that prevents aneurysmal dilation, making them prone to spontaneous hemorrhage when large. AMLs occur sporadically in approximately 80% of cases; the remaining 20% occur in patients with tuberous sclerosis complex (TSC), where they are typically multiple, bilateral, and larger. Oncocytomas are benign tumors of the proximal renal tubular cells that represent approximately 5% of all solid renal masses — they are composed of oncocytes (cells with densely packed mitochondria producing characteristic eosinophilic cytoplasm) and are most often diagnosed in men over 60.
Other contributing factors.
Polycystic kidney disease — in both its autosomal dominant (ADPKD, caused by PKD1 or PKD2 mutations) and autosomal recessive forms — produces numerous bilateral cysts that progressively replace normal renal parenchyma and impair function. ADPKD is the most common inherited kidney disease, affecting approximately 1 in 400–1000 people, and is also associated with intracranial berry aneurysms (in 5–10% of patients), liver cysts, and mitral valve prolapse. Complex inflammatory masses — xanthogranulomatous pyelonephritis (XGP), renal abscess, and focal bacterial nephritis — can produce solid-appearing mass-like lesions that mimic tumors on imaging but are diagnosed by clinical context and specific imaging features.
Symptoms
The vast majority of benign renal masses are entirely asymptomatic and are discovered incidentally on abdominal imaging ordered for an unrelated reason — CT for abdominal pain, ultrasound for urinary symptoms, or MRI for back pain. Large simple cysts occasionally cause a dull flank ache from distension. The most clinically significant symptom associated with a benign renal mass is sudden severe flank pain with hypotension from spontaneous retroperitoneal hemorrhage of a large angiomyolipoma — "Wunderlich syndrome" — which can be life-threatening and may require emergency embolization. Hematuria is less commonly associated with benign masses than with renal cell carcinoma but can occur with large AMLs or after minor trauma to a cyst. Patients with ADPKD develop progressive renal insufficiency, flank pain from enlarging cysts, hypertension, and recurrent urinary tract infections; approximately 50% reach end-stage renal disease by age 60.
Diagnosis
Renal masses are most often initially detected on ultrasound (simple cysts appear as anechoic fluid collections with posterior acoustic enhancement) or CT. Once identified, MRI is the definitive characterization study for most renal masses, particularly when CT findings are indeterminate, when contrast cannot be used (due to iodinated contrast allergy or renal impairment), or when precise fat quantification is needed.
An MRI of the abdomen provides multiparametric renal mass characterization that no other modality can match. Fat detection is the most powerful tool: macroscopic fat within a renal mass — identified as T1-bright signal that drops out on fat-saturated sequences — is essentially diagnostic of AML, as fat-containing renal cell carcinoma is exceedingly rare. Fat-poor AMLs (which lack macroscopic fat) are identified by their signal drop on opposed-phase chemical shift imaging compared to in-phase sequences — a specific MRI technique that detects intracellular lipid not visible on fat saturation. Diffusion-weighted imaging (DWI) adds malignancy risk stratification — benign masses show high ADC values (facilitated diffusion); malignant masses show low ADC values (restricted diffusion). The Bosniak classification system (version 2019) grades cystic renal masses by MRI features: Bosniak I (simple, anechoic, no enhancement — benign, no follow-up); Bosniak II (minimal complexity — benign, no follow-up); Bosniak IIF (mildly complex — requires 6-month and annual MRI surveillance); Bosniak III (moderately complex with thick walls or septa — approximately 50% malignant, surgical evaluation recommended); Bosniak IV (clearly malignant — surgical resection). Oncocytomas show a characteristic central stellate scar on MRI in approximately 30% of cases but cannot be reliably distinguished from chromophobe RCC without biopsy — the two are often managed together as "oncocytic renal neoplasms."
Classification
Common benign renal masses with their characteristic MRI features and management implications.
- Simple cyst (Bosniak I): Thin-walled, anechoic, no enhancement, no internal complexity. No malignant potential. No treatment or follow-up required regardless of size.
- Complex cyst (Bosniak IIF–III): Increasing wall thickness, septa, or calcifications. Managed per Bosniak category — IIF requires surveillance MRI; III warrants surgical evaluation given ~50% malignancy risk.
- Angiomyolipoma (AML): Macroscopic fat = confidently benign on MRI. Fat-poor AML requires chemical shift imaging. Observe if <4 cm and asymptomatic; embolize or surgically resect if ?4 cm or symptomatic.
- Oncocytoma: Benign solid renal tumor; characteristic central scar in 30% of cases. Cannot reliably distinguish from chromophobe RCC on imaging — biopsy or surgical resection often required for definitive diagnosis.
- ADPKD: Multiple bilateral cysts of varying complexity. Annual blood pressure control, renal function monitoring, and tolvaptan (vasopressin receptor antagonist — the only approved disease-modifying therapy) in rapidly progressive disease.
- Inflammatory mass (XGP, abscess, focal nephritis): Diagnosed by clinical context (fever, infection history, urinalysis). Treated with antibiotics; drainage or nephrectomy for XGP.
Treatments
Most benign renal masses require no treatment — accurate MRI characterization is the intervention, converting patient anxiety about a kidney mass into confident reassurance or a clear management plan.
Observation: Simple cysts (Bosniak I–II) require no follow-up imaging — the diagnosis is definitive and the prognosis is excellent regardless of size. Small AMLs under 4 cm without symptoms are observed with MRI every 1–2 years to confirm stability. Oncocytomas confirmed by biopsy in patients with significant surgical risk may be observed with serial MRI if they remain stable.
Intervention for angiomyolipomas.
Selective arterial embolization is the preferred treatment for AMLs ?4 cm or those with symptomatic bleeding — the feeding vessels are embolized under fluoroscopic guidance, causing infarction of the AML without removing the kidney. Embolization preserves renal function while eliminating the hemorrhage risk. Surgical partial nephrectomy is reserved for failed embolization or diagnostic uncertainty. In tuberous sclerosis complex-associated AMLs, mTOR inhibitors (everolimus, sirolimus) reduce AML size and are the medical treatment of choice for multiple or bilateral lesions.
Management of symptomatic or complex cysts.
Bosniak IIF cysts are followed with MRI at 6 months, then annually for 5 years — upgrade to Bosniak III on follow-up prompts surgical evaluation. Large symptomatic simple cysts causing significant pain are treated with percutaneous aspiration and sclerotherapy (ethanol injection) or laparoscopic deroofing. ADPKD cysts are not individually treated; tolvaptan slows kidney volume growth and preserves GFR in patients with rapidly progressive disease.
When findings are uncertain.
Solid indeterminate masses — particularly those where oncocytoma vs. chromophobe RCC cannot be differentiated on imaging — are evaluated with percutaneous renal biopsy (under CT or ultrasound guidance, with sensitivity exceeding 90% for malignancy) or with surgical excision by partial nephrectomy, which is both diagnostic and therapeutic. The threshold for biopsy vs. resection depends on the patient's surgical risk, age, and degree of imaging suspicion for malignancy.
Get an MRI to Confirm Your Diagnosis
Before surgical planning or starting treatment, a clear MRI diagnosis ensures the right path forward. First Look MRI offers self-pay Abdomen MRI scans — no doctor's order or insurance required — at our locations in Georgia, Texas, and Colorado.